【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 617次   下载 583 本文二维码信息
码上扫一扫!
外泌体程序性死亡蛋白1在肺癌中的研究进展
胡家勋,唐昊*
0
(海军军医大学(第二军医大学)第二附属医院呼吸与危重症医学科, 上海 200003
*通信作者)
摘要:
近年来,以程序性死亡蛋白-1(PD-1)/程序性死亡蛋白配体-1(PD-L1)抑制剂为代表的免疫治疗对肺癌显示出明显疗效,但在不同的肺癌患者中PD-1/PD-L1抑制剂的疗效存在显著差异。研究发现外泌体PD-L1(ePD-L1)可以代替肺癌细胞PD-L1抑制T细胞活化,产生免疫抵抗,同时还能将PD-L1转移到次级细胞发挥免疫耐受作用,影响免疫治疗的效果。本文对外泌体及ePD-L1的分离与检测方法、ePD-L1的免疫抑制作用及ePD-L1在肺癌进展和免疫治疗中的作用机制进行综述。
关键词:  外泌体  程序性死亡蛋白-1  程序性死亡蛋白配体-1  肺肿瘤  免疫疗法
DOI:10.16781/j.CN31-2187/R.20210819
投稿时间:2021-08-19修订日期:2022-04-12
基金项目:国家自然科学基金(82070036).
Exosomal programmed death-1 in lung cancer: research progress
HU Jia-xun,TANG Hao*
(Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200003, China
*Corresponding author)
Abstract:
In recent years, immunotherapy represented by programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has shown remarkable efficacy for lung cancer. However, there are significant differences in the efficacies of PD-1/PD-L1 inhibitors in different patients with lung cancer. Studies have found that exosomal PD-L1 (ePD-L1) can replace the PD-L1 from lung cancer cells to inhibit the activation of T cell and produce immune resistance. At the same time, it can transfer PD-L1 to secondary cells to play the role of immune tolerance and affect the efficacy of immunotherapy. This paper reviews the methods of separation and detection of exosomes and ePD-L1, the immunosuppressive effect of ePD-L1, and the mechanism of ePD-L1 in the progress of lung cancer and immunotherapy.
Key words:  exosomes  programmed death-1  programmed death-ligand 1  lung neoplasins  immunotherapy